- Ensysce Biosciences shares skyrocket nearly 100% after securing a key patent for its innovative methadone prodrug.
- Analysts project significant upside potential, with an average price target suggesting over 1,100% growth.
- Current consensus marks Ensysce as "Outperform," underscoring its promising market position.
Shares of Ensysce Biosciences (ENSC, Financial) experienced a remarkable surge, climbing nearly 100%, following a pivotal development. The U.S. Patent and Trademark Office granted approval for its novel methadone prodrug, PF9001. This breakthrough targets opioid use disorder while mitigating the risks of cardiotoxicity, featuring Ensysce’s proprietary TAAP and MPAR abuse-deterrent technologies, enhancing overdose protection.
Wall Street Analysts Forecast
Market analysts are projecting a robust future for Ensysce Biosciences Inc. According to the one-year price targets set by two analysts, the average target price for Ensysce Biosciences Inc (ENSC, Financial) stands at $46.73. This forecast includes a high estimate of $75.00 and a low estimate of $18.45. These projections suggest an impressive upside of 1,173.16% from the current stock price of $3.67. For more detailed estimates, visit the Ensysce Biosciences Inc (ENSC) Forecast page.
Moreover, based on consensus recommendations from one brokerage firm, Ensysce Biosciences Inc's (ENSC, Financial) average recommendation is pegged at 2.0, translating to an "Outperform" rating. This rating falls on a scale where 1 indicates a Strong Buy and 5 represents Sell, signifying positive sentiment from the investing community.
